Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies
Last Updated: Tuesday, May 13, 2025
A phase I study evaluating the safety of ROR1 CAR T cells. The researchers observed antitumor activity in chronic lymphocytic leukemia, but this was limited in triple-negative breast cancer and non–small cell lung cancer. The ROR1 CAR-T cells were well tolerated in most patients, although there was one dose-limiting toxicity at dose level 4 in a patient with advanced non–small cell lung cancer.
Advertisement
News & Literature Highlights